[go: up one dir, main page]

WO2002039990A3 - Method for screening anti-proliferative compounds and inhibiting tumor growth - Google Patents

Method for screening anti-proliferative compounds and inhibiting tumor growth Download PDF

Info

Publication number
WO2002039990A3
WO2002039990A3 PCT/EP2001/013076 EP0113076W WO0239990A3 WO 2002039990 A3 WO2002039990 A3 WO 2002039990A3 EP 0113076 W EP0113076 W EP 0113076W WO 0239990 A3 WO0239990 A3 WO 0239990A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor growth
inhibiting tumor
screening anti
proliferative compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/013076
Other languages
French (fr)
Other versions
WO2002039990A2 (en
Inventor
Penny Elisabeth Phillips
Patrick Andre Schindler
Harry Towbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to JP2002542365A priority Critical patent/JP2004514122A/en
Priority to EP01996369A priority patent/EP1337854A2/en
Priority to AU2002217020A priority patent/AU2002217020A1/en
Priority to US10/416,669 priority patent/US20040048318A1/en
Publication of WO2002039990A2 publication Critical patent/WO2002039990A2/en
Publication of WO2002039990A3 publication Critical patent/WO2002039990A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a novel method for evaluating the antiproliferative activity of compounds having MetAP inhibitory activity, as well as a method for screening compounds that inhibit angiogenesis or growth of tumors. The invention additionally provides a method for monitoring the progress of treatment for controlling angiogenesis or the growth of tumors.
PCT/EP2001/013076 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth Ceased WO2002039990A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002542365A JP2004514122A (en) 2000-11-14 2001-11-12 Methods for screening antiproliferative compounds and inhibiting tumor growth
EP01996369A EP1337854A2 (en) 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth
AU2002217020A AU2002217020A1 (en) 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth
US10/416,669 US20040048318A1 (en) 2000-11-14 2001-12-11 Method for screening anti-proliferative compounds and method for inhibiting tumor growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24848900P 2000-11-14 2000-11-14
US60/248,489 2000-11-14

Publications (2)

Publication Number Publication Date
WO2002039990A2 WO2002039990A2 (en) 2002-05-23
WO2002039990A3 true WO2002039990A3 (en) 2003-03-13

Family

ID=22939368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013076 Ceased WO2002039990A2 (en) 2000-11-14 2001-11-12 Method for screening anti-proliferative compounds and inhibiting tumor growth

Country Status (4)

Country Link
EP (1) EP1337854A2 (en)
JP (1) JP2004514122A (en)
AU (1) AU2002217020A1 (en)
WO (1) WO2002039990A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412843A (en) * 2003-07-25 2006-09-26 Novartis Ag substituted lactams and their use as anticancer agents
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
FR2878528B1 (en) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2878525B1 (en) 2004-11-29 2007-02-23 Aventis Pharma Sa BENGAMIDES HAVING SUBSTITUTED CAPROLACTAM CYCLE, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901555A1 (en) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINE, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901556A1 (en) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE DERIVATIVES, THEIR PREPARATION, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2901554B1 (en) 2006-05-24 2011-04-01 Sanofi Aventis 2-ALCOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZAZEPINE, PREPARATION THEREOF, COMPOSITIONS CONTAINING SAME AND USE THEREOF
FR2926463B1 (en) * 2008-01-22 2010-08-13 Centre Nat Rech Scient USE OF AMINOPEPTIDASE INHIBITORS OR AZAINDOLE COMPOUNDS FOR PREVENTING OR TREATING CANCER METASTASES OF EPITHELIAL ORIGIN
AU2009313167C1 (en) * 2008-11-06 2014-06-12 Merck Patent Gmbh Use of EEF1A as biomarker for screening of MetAP2 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARTIN H ET AL: "ANTIBODIES AGAINST THE MAJOR BRAIN ISOFORMS OF 14-3-3 PROTEIN AN ANTIBODY SPECIFIC FOR THE N-ACETYLATED AMINO-TERMINUS OF A PROTEIN", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 331, no. 3, 1 October 1993 (1993-10-01), pages 296 - 303, XP002063495, ISSN: 0014-5793 *
PIETROMONACO S F ET AL: "Association of 14-3-3 proteins with centrosomes.", BLOOD CELLS, MOLECULES & DISEASES. UNITED STATES 1996, vol. 22, no. 3, 1996, pages 225 - 237, XP002222680, ISSN: 1079-9796 *
YAFFE M B ET AL: "The structural basis for 14-3-3: phosphopeptide binding specificity", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 91, no. 7, 26 December 1997 (1997-12-26), pages 961 - 971, XP002090547, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
EP1337854A2 (en) 2003-08-27
AU2002217020A1 (en) 2002-05-27
JP2004514122A (en) 2004-05-13
WO2002039990A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2002076977A3 (en) Rho-kinase inhibitors
AU2002336030A1 (en) Methods for preventing, treating or delaying cardiac toxicity using neuregulin
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
GB0300789D0 (en) Stimulation method for the sphenopalatine ganglia,sphenopalatine nerve,or vidian nerve for treatment of medical conditions
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
AU2003297197A8 (en) Method for increasing the efficacy of agricultural chemicals
WO2002039990A3 (en) Method for screening anti-proliferative compounds and inhibiting tumor growth
WO2004032908A3 (en) Method of inhibiting angiogenesis
MXPA02012907A (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity.
WO2003066885A3 (en) Method for screening for compounds having hdac inhibitory activity
EP1404339A4 (en) Method for treating fibrotic diseases or other indications vi
AP2003002834A0 (en) Method of treating of demyelinating disease or conditions.
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
WO2004021988A3 (en) Treatment of pain by inhibition of p38 map kinase
AP2004003070A0 (en) The method of treating cancer.
WO2005005382A3 (en) Compounds, compositions and methods
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2004100873A3 (en) Compounds, compositions, and methods
MXPA04000805A (en) Peptides having antiangiogenic activity.
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
CA2534489A1 (en) Inhibitors of cathepsin s
AU2003297281A8 (en) Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TR TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001996369

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002542365

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001996369

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10416669

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001996369

Country of ref document: EP